The Filing Desk

Aquestive Therapeutics

AQST · Nasdaq · Health Care · Financials, fiscal 2017 to 2025

AQST · Last close · November 13, 2026
$3.91
Value Aquestive Therapeutics yourself

Aquestive Therapeutics' revenue fell 22.6% to $44 million in fiscal 2025. Its operating margin was −159.5%, down from −53.5% a year earlier. Free cash flow was −$53 million. The diluted share count rose 23.3%.

Aquestive Therapeutics, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 4, 2026 · 0001398733-26-000018 Updated
Revenue
$44M
22.6%
Operating margin
−159.5%
106.0 pts
Net income
−$84M
 
Free cash flow
−$53M
 
Return on equity
—
 
Market cap
$491M
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Aquestive Therapeutics does

Aquestive Therapeutics is a drug company that develops medicines meant to be given in ways other than injections and other inconvenient routes. Its main technology is PharmFilm, a thin film about the size of a postage stamp that dissolves in the mouth and delivers a drug into the bloodstream. It says it has been the main maker of oral films for prescription drugs.

It makes money from four licensed products that its partners sell in the U.S. and elsewhere. Aquestive is the exclusive manufacturer of these products and makes them at its plant in Portage, Indiana. It also works with other drug companies to bring new drugs to market using its technology.

Its main candidate in development is Anaphylm, an epinephrine film for severe allergic reactions including anaphylaxis, which needs no device. The FDA sent the company a complete response letter for it, meaning the agency did not approve it as submitted. Aquestive is also developing a platform of epinephrine prodrugs, which are compounds the body converts into epinephrine. Its headquarters and main laboratories are in Warren, New Jersey.

Its biggest risks, as it describes them

  • Anaphylm may not win approval, after the FDA's complete response letter.
  • Clinical trials of its candidates may be delayed, halted or ended.
  • It has limited experience selling its own products and may lack the people and resources to launch them.
  • Its licensed and proprietary products may not gain acceptance from patients, doctors and pharmacists.
  • Competition from other drug companies, and legal actions from competitors or collaborators.
From Aquestive Therapeutics's annual report on Form 10-K, filed March 4, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Aquestive Therapeutics lost money in fiscal 2025: a net loss of $84 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments28272472121
Debt incl. finance leases—33454545
Net debt (negative means net cash)—621−26−76
Net debt to EBITDA—————
Debt to equity—————
Interest coverage−3.5x−6.4x−2.4x−2.8x−6.4x
Current ratio2.1x1.0x2.2x4.7x3.1x
Quick ratio2.0x0.9x1.9x4.4x3.0x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Aquestive Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Aquestive Therapeutics reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 95 of 92 of 9
Rule of 40−8.5%−48.6%−141.6%
Altman Z''−17.98−9.62−8.08
Accruals ratio−2.6%−10.6%−23.9%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassPass
Current ratio rosePassPassFail
Share count didn't riseFailFailFail
Gross margin roseFailPassFail
Revenue rose relative to assetsPassPassFail
F-score4 of 95 of 92 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Aquestive Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Aquestive TherapeuticsFY25−22.6%−159.5%−119.0%——2
Ocular TherapeutixFY25−18.5%−519.8%−417.5%——4Compare
Agios PharmaceuticalsFY2548.0%−873.9%−698.3%———Compare
Nektar TherapeuticsFY25−43.9%−253.7%−377.8%——2Compare
Tango TherapeuticsFY2548.3%−178.4%−224.3%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

9 years of figures

Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue676753465148515844
Revenue growth—0.8%−22.0%−12.8%10.9%−6.2%6.1%13.8%−22.6%
Gross profit——3233—28304026
Research and development222321201718132017
Operating income−0−49−53−43−35−42−15−31−71
Net income−9−61−66−56−70−54−8−44−84
Diluted EPS (US$)—−2.96−2.61−1.66−1.85−1.12−0.13−0.51−0.78
Diluted shares (millions)—21253438496187107
Cash flow
Cash from operations6−13−60−46−33−10−6−36−52
Capital expenditure221011101
Free cash flow4−15−61−46−34−11−7−36−53
Dividends paid000000000
Share buybacks000000000
Acquisitions000000000
Stock-based compensation0307774378
Balance sheet at fiscal year end
Cash and short-term investments1761493228272472121
Debt incl. finance leases——7052—33454545
Total assets43877863625757101160
Total liabilities707785111144176164162194
Shareholders' equity−2610−6−48−82−119−106−60−34
Margins and ratios
Gross margin——61.3%71.7%—59.3%58.8%69.0%58.4%
Operating margin−0.2%−72.6%−100.1%−93.5%−68.2%−88.2%−29.9%−53.5%−159.5%
Net margin−13.4%−91.0%−125.9%−121.7%−138.8%−114.1%−15.6%−76.7%−188.1%
Free cash flow margin5.6%−22.0%−115.7%−100.3%−66.7%−22.7%−14.6%−62.4%−119.0%
Rule of 40 (growth + FCF margin)—−21.2%−137.7%−113.1%−55.8%−28.9%−8.5%−48.6%−141.6%
Return on capital—————————
Return on equity—————————
Return on assets—−94.5%−80.1%−78.9%−113.0%−91.4%−13.8%−55.6%−64.0%
Net debt to EBITDA—————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Aquestive Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Aquestive Therapeutics.